This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jud R. Scholtz, MD
580 Arastradero Rd Palo Alto, CA 94306

Arch Dermatol. 1985;121(1):21-22.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

In the May ARCHIVES, Kumari¹ described 75 patients with vitiligo treated with clobetasol propionate. Twenty-five patients with facial involvement, including the eyelids, were treated with a 0.05% ointment, applied twice daily for a period of eight weeks. The maximum amount was 25 g (12.5 mg clobetasol propionate) per course. The amounts applied to the eyelids are not stated. When needed, a second course was given after an interval of four months without treatment. The report stated that these patients were carefully observed for ocular side effects and that none were noted. It is presumed, but not specifically stated, that intraocular pressure was measured in these patients.

Howell² recommended that patients receiving topical steroid treatment to eyelids for longer than one to two weeks should be monitored for IOP by an ophthalmologist. If indeed there were no measurable (even though transient) increases in IOP in Kumari's . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?